Correlation Between Reviva Pharmaceuticals and Blueprint Medicines

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Reviva Pharmaceuticals and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Reviva Pharmaceuticals and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Reviva Pharmaceuticals Holdings and Blueprint Medicines Corp, you can compare the effects of market volatilities on Reviva Pharmaceuticals and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Reviva Pharmaceuticals with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Reviva Pharmaceuticals and Blueprint Medicines.

Diversification Opportunities for Reviva Pharmaceuticals and Blueprint Medicines

0.59
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Reviva and Blueprint is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Reviva Pharmaceuticals Holding and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Reviva Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Reviva Pharmaceuticals Holdings are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Reviva Pharmaceuticals i.e., Reviva Pharmaceuticals and Blueprint Medicines go up and down completely randomly.

Pair Corralation between Reviva Pharmaceuticals and Blueprint Medicines

Given the investment horizon of 90 days Reviva Pharmaceuticals Holdings is expected to under-perform the Blueprint Medicines. In addition to that, Reviva Pharmaceuticals is 1.53 times more volatile than Blueprint Medicines Corp. It trades about -0.14 of its total potential returns per unit of risk. Blueprint Medicines Corp is currently generating about 0.03 per unit of volatility. If you would invest  8,682  in Blueprint Medicines Corp on December 30, 2024 and sell it today you would earn a total of  190.00  from holding Blueprint Medicines Corp or generate 2.19% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Reviva Pharmaceuticals Holding  vs.  Blueprint Medicines Corp

 Performance 
       Timeline  
Reviva Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Reviva Pharmaceuticals Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.
Blueprint Medicines Corp 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Blueprint Medicines Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound primary indicators, Blueprint Medicines is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Reviva Pharmaceuticals and Blueprint Medicines Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Reviva Pharmaceuticals and Blueprint Medicines

The main advantage of trading using opposite Reviva Pharmaceuticals and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Reviva Pharmaceuticals position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.
The idea behind Reviva Pharmaceuticals Holdings and Blueprint Medicines Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments